MiR-135a has been identified as an inhibitor of angiogenesis in metastatic gastric cancer, specifically though modulation of p53 and focal adhesion kinase (FAK), which activates MAPK and subsequently VEGF (154). The gene discussed is VEGFA; the disease is gastric cancer.